基于倾向性评分匹配法的检测阴性研究:2月龄至6岁儿童无细胞百日咳疫苗保护效果
2024年在浙江省哨点监测医院开展检测阴性病例对照研究,纳入658名因咳嗽就诊并接受百日咳核酸检测的2月龄至6岁儿童,经倾向性评分1∶1匹配后病例组和对照组各203例。结果显示,aPV对百日咳的保护效果随剂次增加而提升,对预防住院效果更好,且末次接种后保护效果随时间迅速衰减。
要点
- 1~2剂、3剂、4剂aPV对百日咳的VE分别为52.46%、65.22%、72.21%。
- 预防百日咳住院的VE:1~3剂为80.95%,4剂为86.79%。
- 完成4剂后间隔<2年VE为91.15%,≥4年降至49.92%。
核心结论
- aPV对2月龄至6岁儿童百日咳的保护效果随接种剂次增加而提升,对预防百日咳住院的效果更好。
- aPV保护效果随末次接种后时间推移而迅速衰减,建议按调整后的新版百日咳免疫程序,及时、全程接种。
研究设计与样本
- 2024年在浙江省百日咳哨点监测医院开展检测阴性病例对照研究,对象为因咳嗽就诊并接受百日咳核酸检测的2月龄至6岁儿童。
- 病例为百日咳核酸检测阳性者,对照为检测阴性者,按倾向性评分卡钳匹配法1∶1匹配。
- 共纳入658例,其中31.76%(209例)核酸检测阳性;匹配后病例组和对照组各203例。
- 使用条件logistic回归模型计算OR和VE。
主要发现
- 1~2剂aPV对百日咳的VE为52.46%(95%CI:-39.82%~83.84%),3剂为65.22%(95%CI:6.86%~87.02%),4剂为72.21%(95%CI:34.33%~88.24%)。
- 预防百日咳住院的VE:1~3剂为80.95%(95%CI:31.38%~94.71%),4剂为86.79%(95%CI:51.89%~96.37%)。
- 完成4剂且接种后间隔<2年VE为91.15%(95%CI:67.61%~97.58%),间隔2年为84.70%(95%CI:43.71%~95.84%),间隔3年为56.23%(95%CI:-47.58%~87.02%),间隔≥4年为49.92%(95%CI:-83.74%~86.35%)。
临床怎么用
- 作者建议按调整后的新版百日咳免疫程序,及时、全程接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the protective effectiveness (VE) of the acellular pertussis vaccine (aPV) against pertussis in children aged 2 months to 6 years. Methods: A test-negative case-control study was conducted among children aged 2 months to 6 years who sought medical care for cough and underwent pertussis nucleic acid testing at sentinel surveillance hospitals in Zhejiang Province in 2024. Cases were defined as those with positive pertussis nucleic acid test results, while controls were test-negative individuals matched 1∶1 based on propensity scores using the caliper matching method. Conditional logistic regression models were used to calculate odds ratios (ORs) and VEs. Results: Among the 658 participants, 31.76% (209 cases) tested positive for pertussis. After propensity score matching, 203 cases and 203 controls were included in the analysis. The VE of 1-2, 3, and 4 doses of aPV against pertussis was 52.46% (95%CI:-39.82%-83.84%), 65.22% (95%CI: 6.86%-87.02%), and 72.21% (95%CI: 34.33%-88.24%), respectively. For pertussis-related hospitalization, the VE of 1-3 and 4 doses was 80.95% (95%CI:31.38%-94.71%) and 86.79% (95%CI: 51.89%-96.37%). The VE for those who completed 4 doses of vaccination and had intervals of less than 2 years, 2 years, 3 years, and 4 years or more after vaccination were 91.15% (95%CI: 67.61%-97.58%), 84.70% (95%CI: 43.71%-95.84%),56.23% (95%CI:-47.58%-87.02%), and 49.92% (95%CI:-83.74%-86.35%), respectively. Conclusion: The VE of aPV against pertussis in children aged 2 months to 6 years increases with the number of doses administered, and it is more effective in preventing hospitalization due to pertussis. The VE declines rapidly over time after the last dose. It is recommended to follow the new pertussis immunization program for timely and full vaccination. 目的: 评价含无细胞百日咳成分疫苗(aPV)对2月龄~6岁儿童百日咳的保护效果(VE)。 方法: 选取2024年在浙江省百日咳哨点监测医院因咳嗽就诊并进行了百日咳核酸检测的2月龄至6岁儿童,采用检测阴性病例对照研究设计,将百日咳核酸检测阳性者作为病例组,根据倾向性评分值采用卡钳匹配的方法1∶1匹配检测阴性者作为对照组,使用条件logistic回归模型分析百日咳的保护效果。 结果: 共纳入研究对象658例,其中31.76%(209例)百日咳核酸阳性。倾向评分匹配后,纳入病例组和对照组各203例,1~2剂aPV对百日咳的VE为52.46%(95%CI:-39.82%~83.84%),3剂VE为65.22%(95%CI:6.86%~87.02%),4剂VE为72.21%(95%CI:34.33%~88.24%)。对于预防百日咳住院,1~3剂aPV的VE为80.95%(95%CI:31.38%~94.71%),4剂VE为86.79%(95%CI:51.89%~96.37%)。完成4剂次接种且接种后时间间隔<2年、2年、3年、≥4年的VE分别是91.15%(95%CI:67.61%~97.58%),84.70%(95%CI:43.71%~95.84%),56.23%(95%CI:-47.58%~87.02%)、49.92%(95%CI:-83.74%~86.35%)。 结论: aPV对2月龄至6岁儿童百日咳的保护效果随接种剂次增加而提升,对预防百日咳住院的效果更好。aPV保护效果随末次接种后时间推移而迅速衰减,建议按调整后的新版百日咳免疫程序,及时、全程接种。.
引用
- Zhu Y, Zhou Y, Qi XH, et al. [A test-negative study on the protective effectiveness of acellular pertussis vaccine in children aged 2 months to 6 years based on propensity score matching method]. Zhonghua Yu Fang Yi Xue Za Zhi. 2025. PMID: 41287319. doi:10.3760/cma.j.cn112150-20250617-00559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。